Dipeptidyl peptidase in autoimmune pathophysiology

Advances in Clinical Chemistry

Volumn 53, Issue C, 2011, Pages 51-84

  Ohnuma, Kei ^a   Hosono, Osamu ^a   Dang, Nam H ^b   Morimoto, Chikao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650967660     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385855-9.00003-5     Document Type: Chapter

References (196)

1. Hopsu-Havu V.K., Glenner G.G. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie 1966, 7:197-201.
2. Tanaka T., Camerini D., Seed B., Torimoto Y., Dang N.H., Kameoka J., Dahlberg H.N., Schlossman S.F., Morimoto C. Cloning and functional expression of the T cell activation antigen CD26. J. Immunol. 1992, 149:481-486.
3. Morimoto C., Torimoto Y., Levinson G., Rudd C.E., Schrieber M., Dang N.H., Letvin N.L., Schlossman S.F. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J. Immunol. 1989, 143:3430-3439.
4. Fleischer B. CD26: a surface protease involved in T cell activation. Immunol. Today 1994, 15:180-184.
5. Morimoto C., Schlossman S.F. The structure and function of CD26 in the T cell immune response. Immunol. Rev. 1998, 161:55-70.
6. von Bonin A., Huhn J., Fleischer B. Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T cell activation pathway. Immunol. Rev. 1998, 161:43-53.
7. Dang N.H., Torimoto Y., Sugita K., Daley J.F., Schow P., Prado C., Schlossman S.F., Morimoto C. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J. Immunol. 1990, 145:3963-3971.
8. Fox D.A., Hussey R.E., Fitzgerald K.A., Acuto O., Poole C., Palley L., Daley J.F., Schlossman S.F., Reinherz E.L. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J. Immunol. 1984, 133:1250-1256.
9. Marguet D., Bernard A.M., Vivier I., Darmoul D., Naquet P., Pierres M. cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. J. Biol. Chem. 1992, 267:2200-2208.
10. Abbott C.A., Baker E., Sutherland G.R., McCaughan G.W. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994, 40:331-338.
11. Morrison M.E., Vijayasaradhi S., Engelstein D., Albino A.P., Houghton A.N. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J. Exp. Med. 1993, 177:1135-1143.
12. Stange T., Kettmann U., Holzhausen H.J. Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells. Eur. J. Histochem. 2000, 44:157-164.
13. Vahl T.P., Paty B.W., Fuller B.D., Prigeon R.L., D'Alessio D.A. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J. Clin. Endocrinol. Metab. 2003, 88:1772-1779.
14. Yan S., Marguet D., Dobers J., Reutter W., Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur. J. Immunol. 2003, 33:1519-1527.
15. Gotoh H., Hagihara M., Nagatsu T., Iwata H., Miura T. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin. Chem. 1989, 35:1016-1018.
16. Hildebrandt M., Rose M., Ruter J., Salama A., Monnikes H., Klapp B.F. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2001, 36:1067-1072.
17. Kobayashi H., Hosono O., Mimori T., Kawasaki H., Dang N.H., Tanaka H., Morimoto C. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J. Rheumatol. 2002, 29:1858-1866.
18. Reinhold D., Bank U., Tager M., Ansorge S., Wrenger S., Thielitz A., Lendeckel U., Faust J., Neubert K., Brocke S. DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front. Biosci. 2008, 13:2356-2363.
19. Sromova L., Mareckova H., Sedova L., Balaziova E., Sedo A. Dipeptidyl peptidase-IV in synovial fluid and in synovial fluid mononuclear cells of patients with rheumatoid arthritis. Clin. Chim. Acta 2010, 411:1046-1050.
20. Korom S., De Meester I., Maas E., Stein A., Wilker S., Jung F., Weimer R., Brendel M.D., Ernst W., Friemann S., Linder R., Grimm H., Padberg W., Scharpe S., Kupiec-Weglinski J.W., Schwemmle K. CD26 expression and enzymatic activity in recipients of kidney allografts. Transplant. Proc. 2002, 34:1753-1754.
21. Kameoka J., Sato T., Torimoto Y., Sugita K., Soiffer R.J., Schlossman S.F., Ritz J., Morimoto C. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood 1995, 85:1132-1137.
22. Lambeir A.M., Durinx C., Scharpe S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40:209-294.
23. Ohnuma K., Dang N.H., Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008, 29:295-301.
24. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol. Sci. 2009, 30:600-607.
25. Ogata S., Misumi Y., Ikehara Y. Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. J. Biol. Chem. 1989, 264:3596-3601.
26. Darmoul D., Lacasa M., Baricault L., Marguet D., Sapin C., Trotot P., Barbat A., Trugnan G. Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J. Biol. Chem. 1992, 267:4824-4833.
27. Misumi Y., Hayashi Y., Arakawa F., Ikehara Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim. Biophys. Acta 1992, 1131:333-336.
28. Thompson M.A., Ohnuma K., Abe M., Morimoto C., Dang N.H. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev. Med. Chem. 2007, 7:253-273.
29. Bernard A.M., Mattei M.G., Pierres M., Marguet D. Structure of the mouse dipeptidyl peptidase IV (CD26) gene. Biochemistry 1994, 33:15204-15214.
30. Frerker N., Wagner L., Wolf R., Heiser U., Hoffmann T., Rahfeld J.U., Schade J., Karl T., Naim H.Y., Alfalah M., Demuth H.U., von Horsten S. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides 2007, 28:257-268.
31. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diab. Care 2007, 30:1335-1343.
32. Goldstein L.A., Ghersi G., Pineiro-Sanchez M.L., Salamone M., Yeh Y., Flessate D., Chen W.T. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim. Biophys. Acta 1997, 1361:11-19.
33. Rettig W.J., Su S.L., Fortunato S.R., Scanlan M.J., Raj B.K., Garin-Chesa P., Healey J.H., Old L.J. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int. J. Cancer 1994, 58:385-392.
34. Scanlan M.J., Raj B.K., Calvo B., Garin-Chesa P., Sanz-Moncasi M.P., Healey J.H., Old L.J., Rettig W.J. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA 1994, 91:5657-5661.
35. Mathew S., Scanlan M.J., Mohan Raj B.K., Murty V.V., Garin-Chesa P., Old L.J., Rettig W.J., Chaganti R.S. The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 1995, 25:335-337.
36. Niedermeyer J., Enenkel B., Park J.E., Lenter M., Rettig W.J., Damm K., Schnapp A. Mouse fibroblast-activation protein-conserved Fap gene organization and biochemical function as a serine protease. Eur. J. Biochem. 1998, 254:650-654.
37. Abbott C.A., McCaughan G.W., Gorrell M.D. Two highly conserved glutamic acid residues in the predicted β propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett. 1999, 458:278-284.
38. Abbott C.A., Yu D.M., Woollatt E., Sutherland G.R., McCaughan G.W., Gorrell M.D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. 2000, 267:6140-6150.
39. Rasmussen H.B., Branner S., Wiberg F.C., Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 2003, 10:19-25.
40. David F., Bernard A.M., Pierres M., Marguet D. Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases. J. Biol. Chem. 1993, 268:17247-17252.
41. Hooper J.D., Clements J.A., Quigley J.P., Antalis T.M. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 2001, 276:857-860.
42. Fulop V., Bocskei Z., Polgar L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell 1998, 94:161-170.
43. Chien C.H., Huang L.H., Chou C.Y., Chen Y.S., Han Y.S., Chang G.G., Liang P.H., Chen X. One site mutation disrupts dimer formation in human DPP-IV proteins. J. Biol. Chem. 2004, 279:52338-52345.
44. Kahne T., Kroning H., Thiel U., Ulmer A.J., Flad H.D., Ansorge S. Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation. Cell. Immunol. 1996, 170:63-70.
45. Schrader W.P., West C.A., Miczek A.D., Norton E.K. Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction. J. Biol. Chem. 1990, 265:19312-19318.
46. Sauer A.V., Aiuti A. New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. Curr. Opin. Allergy Clin. Immunol. 2009, 9:496-502.
47. Abbott C.A., McCaughan G.W., Levy M.T., Church W.B., Gorrell M.D. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted β propeller domain. Eur. J. Biochem. 1999, 266:798-810.
48. Dong R.P., Tachibana K., Hegen M., Munakata Y., Cho D., Schlossman S.F., Morimoto C. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J. Immunol. 1997, 159:6070-6076.
49. Dinjens W.N., ten Kate J., Wijnen J.T., van der Linden E.P., Beek C.J., Lenders M.H., Khan P.M., Bosman F.T. Distribution of adenosine deaminase-complexing protein in murine tissues. J. Biol. Chem. 1989, 264:19215-19220.
50. Iwaki-Egawa S., Watanabe Y., Fujimoto Y. CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells. Cell. Immunol. 1997, 178:180-186.
51. Franco R., Valenzuela A., Lluis C., Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol. Rev. 1998, 161:27-42.
52. Dong R.P., Kameoka J., Hegen M., Tanaka T., Xu Y., Schlossman S.F., Morimoto C. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J. Immunol. 1996, 156:1349-1355.
53. Hirschhorn R., Nicknam M.N., Eng F., Yang D.R., Borkowsky W. Novel deletion and a new missense mutation (Glu 217 Lys) at the catalytic site in two adenosine deaminase alleles of a patient with neonatal onset adenosine deaminase-severe combined immunodeficiency. J. Immunol. 1992, 149:3107-3112.
54. Richard E., Arredondo-Vega F.X., Santisteban I., Kelly S.J., Patel D.D., Hershfield M.S. The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to CD26 but does not cause immune deficiency. J. Exp. Med. 2000, 192:1223-1236.
55. Santisteban I., Arredondo-Vega F.X., Kelly S., Loubser M., Meydan N., Roifman C., Howell P.L., Bowen T., Weinberg K.I., Schroeder M.L., et al. Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA. Hum. Mol. Genet. 1995, 4:2081-2087.
56. Martin M., Huguet J., Centelles J.J., Franco R. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J. Immunol. 1995, 155:4630-4643.
57. Gines S., Marino M., Mallol J., Canela E.I., Morimoto C., Callebaut C., Hovanessian A., Casado V., Lluis C., Franco R. Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. Biochem. J. 2002, 361:203-209.
58. Bauvois B. A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. Biochem. J. 1988, 252:723-731.
59. Hanski C., Huhle T., Gossrau R., Reutter W. Direct evidence for the binding of rat liver DPP IV to collagen in vitro. Exp. Cell Res. 1988, 178:64-72.
60. Piazza G.A., Callanan H.M., Mowery J., Hixson D.C. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem. J. 1989, 262:327-334.
61. Loster K., Zeilinger K., Schuppan D., Reutter W. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem. Biophys. Res. Commun. 1995, 217:341-348.
62. Dang N.H., Torimoto Y., Schlossman S.F., Morimoto C. Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. J. Exp. Med. 1990, 172:649-652.
63. Shimizu Y., Shaw S. Lymphocyte interactions with extracellular matrix. FASEB J. 1991, 5:2292-2299.
64. Mattern T., Reich C., Schonbeck U., Ansorge S., Demuth H.U., Loppnow H., Ulmer A.J., Flad H.D. CD26 (dipeptidyl peptidase i.v.) on human T lymphocytes does not mediate adhesion of these cells to endothelial cells or fibroblasts. Immunobiology 1998, 198:465-475.
65. McCaughan G.W., Gorrell M.D., Bishop G.A., Abbott C.A., Shackel N.A., McGuinness P.H., Levy M.T., Sharland A.F., Bowen D.G., Yu D., Slaitini L., Church W.B., Napoli J. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol. Rev. 2000, 174:172-191.
66. Havre P.A., Abe M., Urasaki Y., Ohnuma K., Morimoto C., Dang N.H. The role of CD26/dipeptidyl peptidase IV in cancer. Front. Biosci. 2008, 13:1634-1645.
67. Huntington N.D., Tarlinton D.M. CD45: direct and indirect government of immune regulation. Immunol. Lett. 2004, 94:167-174.
68. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
69. Ishii T., Ohnuma K., Murakami A., Takasawa N., Kobayashi S., Dang N.H., Schlossman S.F., Morimoto C. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc. Natl. Acad. Sci. USA 2001, 98:12138-12143.
70. Torimoto Y., Dang N.H., Vivier E., Tanaka T., Schlossman S.F., Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J. Immunol. 1991, 147:2514-2517.
71. Kobayashi S., Ohnuma K., Uchiyama M., Iino K., Iwata S., Dang N.H., Morimoto C. Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T cell activation. Blood 2004, 103:1002-1010.
72. Ikushima H., Munakata Y., Ishii T., Iwata S., Terashima M., Tanaka H., Schlossman S.F., Morimoto C. Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. Proc. Natl. Acad. Sci. USA 2000, 97:8439-8444.
73. Ikushima H., Munakata Y., Iwata S., Ohnuma K., Kobayashi S., Dang N.H., Morimoto C. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell. Immunol. 2002, 215:106-110.
74. Herrera C., Morimoto C., Blanco J., Mallol J., Arenzana F., Lluis C., Franco R. Comodulation of CXCR4 and CD26 in human lymphocytes. J. Biol. Chem. 2001, 276:19532-19539.
75. Havre P.A., Abe M., Urasaki Y., Ohnuma K., Morimoto C., Dang N.H. CD26 expression on T cell lines increases SDF-1-α-mediated invasion. Br. J. Cancer 2009, 101:983-991.
76. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
77. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
78. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., Schwartz O., Heard J.M., Clark-Lewis I., Legler D.F., Loetscher M., Baggiolini M., Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T cell-line-adapted HIV-1. Nature 1996, 382:833-835.
79. Oravecz T., Roderiquez G., Koffi J., Wang J., Ditto M., Bou-Habib D.C., Lusso P., Norcross M.A. CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T cell line. Nat. Med. 1995, 1:919-926.
80. Wu L., Paxton W.A., Kassam N., Ruffing N., Rottman J.B., Sullivan N., Choe H., Sodroski J., Newman W., Koup R.A., Mackay C.R. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 1997, 185:1681-1691.
81. Callebaut C., Jacotot E., Blanco J., Krust B., Hovanessian A.G. Increased rate of HIV-1 entry and its cytopathic effect in CD4+/CXCR4+ T cells expressing relatively high levels of CD26. Exp. Cell Res. 1998, 241:352-362.
82. Ohtsuki T., Hosono O., Kobayashi H., Munakata Y., Souta A., Shioda T., Morimoto C. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1 alpha by CD26/dipeptidyl peptidase IV. FEBS Lett. 1998, 431:236-240.
83. Simmons G., Reeves J.D., Hibbitts S., Stine J.T., Gray P.W., Proudfoot A.E., Clapham P.R. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol. Rev. 2000, 177:112-126.
84. Jiang J.D., Wilk S., Li J., Zhang H., Bekesi J.G. Inhibition of human immunodeficiency virus type 1 infection in a T cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. Res. Virol. 1997, 148:255-266.
85. Valenzuela A., Blanco J., Callebaut C., Jacotot E., Lluis C., Hovanessian A.G., Franco R. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J. Immunol. 1997, 158:3721-3729.
86. Blanco J., Valenzuela A., Herrera C., Lluis C., Hovanessian A.G., Franco R. The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression. FEBS Lett. 2000, 477:123-128.
87. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
88. Martinez-Navio J.M., Climent N., Pacheco R., Garcia F., Plana M., Nomdedeu M., Oliva H., Rovira C., Miralles L., Gatell J.M., Gallart T., Mallol J., Lluis C., Franco R. Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T cell activation. Immunology 2009, 128:393-404.
89. Gutheil W.G., Subramanyam M., Flentke G.R., Sanford D.G., Munoz E., Huber B.T., Bachovchin W.W. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc. Natl. Acad. Sci. USA 1994, 91:6594-6598.
90. Reinhold D., Wrenger S., Bank U., Buhling F., Hoffmann T., Neubert K., Kraft M., Frank R., Ansorge S. CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells. Immunobiology 1996, 195:119-128.
91. Subramanyam M., Gutheil W.G., Bachovchin W.W., Huber B.T. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J. Immunol. 1993, 150:2544-2553.
92. Blanco J., Marie I., Callebaut C., Jacotot E., Krust B., Hovanessian A.G. Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26. Exp. Cell Res. 1996, 225:102-111.
93. Huhn J., Olek S., Fleischer B., von Bonin A. The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule. Cell. Immunol. 1999, 192:33-40.
94. Smith R.E., Talhouk J.W., Brown E.E., Edgar S.E. The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding. AIDS Res. Hum. Retroviruses 1998, 14:851-868.
95. Gonzalez-Gronow M., Gawdi G., Pizzo S.V. Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. J. Biol. Chem. 1994, 269:4360-4366.
96. Gonzalez-Gronow M., Kaczowka S., Gawdi G., Pizzo S.V. Dipeptidyl peptidase IV (DPPIV/CD26) is a cell-surface plasminogen receptor. Front. Biosci. 2008, 13:1610-1618.
97. Gonzalez-Gronow M., Weber M.R., Gawdi G., Pizzo S.V. Dipeptidyl peptidase IV (CD26) is a receptor for streptokinase on rheumatoid synovial fibroblasts. Fibrinol. Proteol. 1998, 12:129-135.
98. Ohnuma K., Yamochi T., Uchiyama M., Nishibashi K., Iwata S., Hosono O., Kawasaki H., Tanaka H., Dang N.H., Morimoto C. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Mol. Cell. Biol. 2005, 25:7743-7757.
99. Ohnuma K., Yamochi T., Uchiyama M., Nishibashi K., Yoshikawa N., Shimizu N., Iwata S., Tanaka H., Dang N.H., Morimoto C. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc. Natl. Acad. Sci. USA 2004, 101:14186-14191.
100. Ohnuma K., Uchiyama M., Yamochi T., Nishibashi K., Hosono O., Takahashi N., Kina S., Tanaka H., Lin X., Dang N.H., Morimoto C. Caveolin-1 triggers T cell activation via CD26 in association with CARMA1. J. Biol. Chem. 2007, 282:10117-10131.
101. Durinx C., Neels H., Van der Auwera J.C., Naelaerts K., Scharpe S., De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin. Chem. Lab. Med. 2001, 39:155-159.
102. Hosono O., Homma T., Kobayashi H., Munakata Y., Nojima Y., Iwamoto A., Morimoto C. Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Clin. Immunol. 1999, 91:283-295.
103. Cuchacovich M., Gatica H., Pizzo S.V., Gonzalez-Gronow M. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin. Exp. Rheumatol. 2001, 19:673-680.
104. Tanaka T., Kameoka J., Yaron A., Schlossman S.F., Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Sci. USA 1993, 90:4586-4590.
105. Ohnuma K., Munakata Y., Ishii T., Iwata S., Kobayashi S., Hosono O., Kawasaki H., Dang N.H., Morimoto C. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J. Immunol. 2001, 167:6745-6755.
106. Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., Boykins R., Unsworth E., Norcross M.A. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 1997, 186:1865-1872.
107. Proost P., Struyf S., Schols D., Opdenakker G., Sozzani S., Allavena P., Mantovani A., Augustyns K., Bal G., Haemers A., Lambeir A.M., Scharpe S., Van Damme J., De Meester I. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J. Biol. Chem. 1999, 274:3988-3993.
108. Christopherson K.W., Hangoc G., Mantel C.R., Broxmeyer H.E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004, 305:1000-1003.
109. -/- mice. Exp. Hematol. 2003, 31:1126-1134.
110. Christopherson K.W., Hangoc G., Broxmeyer H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 α-mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol. 2002, 169:7000-7008.
111. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
112. Kirby M., Yu D.M., O'Connor S., Gorrell M.D. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin. Sci. (Lond.) 2009, 118:31-41.
113. Hegen M., Kameoka J., Dong R.P., Schlossman S.F., Morimoto C. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 1997, 90:257-264.
114. Reinhold D., Bank U., Buhling F., Lendeckel U., Faust J., Neubert K., Ansorge S. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 1997, 91:354-360.
115. Reinhold D., Kahne T., Tager M., Lendeckel U., Buhling F., Bank U., Wrenger S., Faust J., Neubert K., Ansorge S. The effect of anti-CD26 antibodies on DNA synthesis and cytokine production (IL-2, IL-10 and IFN-γ) depends on enzymatic activity of DP IV/CD26. Adv. Exp. Med. Biol. 1997, 421:149-155.
116. H 1 subsets. J. Allergy Clin. Immunol. 1997, 100:348-355.
117. Dang N.H., Hafler D.A., Schlossman S.F., Breitmeyer J.B. FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation. Cell. Immunol. 1990, 125:42-57.
118. Gerli R., Muscat C., Bertotto A., Bistoni O., Agea E., Tognellini R., Fiorucci G., Cesarotti M., Bombardieri S. CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin. Immunol. Immunopathol. 1996, 80:31-37.
119. Iwata S., Yamaguchi N., Munakata Y., Ikushima H., Lee J.F., Hosono O., Schlossman S.F., Morimoto C. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int. Immunol. 1999, 11:417-426.
120. Mizokami A., Eguchi K., Kawakami A., Ida H., Kawabe Y., Tsukada T., Aoyagi T., Maeda K., Morimoto C., Nagataki S. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. J. Rheumatol. 1996, 23:2022-2026.
121. Muscat C., Bertotto A., Agea E., Bistoni O., Ercolani R., Tognellini R., Spinozzi F., Cesarotti M., Gerli R. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 1994, 98:252-256.
122. Hegen M., Mittrucker H.W., Hug R., Demuth H.U., Neubert K., Barth A., Fleischer B. Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells. Immunobiology 1993, 189:483-493.
123. Huhn J., Ehrlich S., Fleischer B., von Bonin A. Molecular analysis of CD26-mediated signal transduction in T cells. Immunol. Lett. 2000, 72:127-132.
124. Steeg C., Hartwig U., Fleischer B. Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity. Cell. Immunol. 1995, 164:311-315.
125. Reinhold D., Bank U., Buhling F., Neubert K., Mattern T., Ulmer A.J., Flad H.D., Ansorge S. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiology 1993, 188:403-414.
126. Schon E., Demuth H.U., Eichmann E., Horst H.J., Korner I.J., Kopp J., Mattern T., Neubert K., Noll F., Ulmer A.J., et al. Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand. J. Immunol. 1989, 29:127-132.
127. Schon E., Jahn S., Kiessig S.T., Demuth H.U., Neubert K., Barth A., Von Baehr R., Ansorge S. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur. J. Immunol. 1987, 17:1821-1826.
128. Ohnuma K., Uchiyama M., Hatano R., Takasawa W., Endo Y., Dang N.H., Morimoto C. Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+ T cells. Biochem. Biophys. Res. Commun. 2009, 386:327-332.
129. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 2000, 97:6874-6879.
130. Reinhold D., Goihl A., Wrenger S., Reinhold A., Kuhlmann U.C., Faust J., Neubert K., Thielitz A., Brocke S., Tager M., Ansorge S., Bank U. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. Clin. Chem. Lab. Med. 2009, 47:268-274.
131. Vora K.A., Porter G., Peng R., Cui Y., Pryor K., Eiermann G., Zaller D.M. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol. 2009, 10:19.
132. Flentke G.R., Munoz E., Huber B.T., Plaut A.G., Kettner C.A., Bachovchin W.W. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T cell function. Proc. Natl. Acad. Sci. USA 1991, 88:1556-1559.
133. Kim S.J., Nian C., Doudet D.J., McIntosh C.H. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T cell modulation. Diabetes 2009, 58:641-651.
134. Kim S.J., Nian C., McIntosh C.H. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T cell migration through incretin-dependent and-independent pathways. Diabetes 2010, 59:1739-1750.
135. Buhling F., Junker U., Reinhold D., Neubert K., Jager L., Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol. Lett. 1995, 45:47-51.
136. Stohlawetz P., Hahn P., Koller M., Hauer J., Resch H., Smolen J., Pietschmann P. Immunophenotypic characteristics of monocytes in elderly subjects. Scand. J. Immunol. 1998, 48:324-326.
137. Alijagic S., Moller P., Artuc M., Jurgovsky K., Czarnetzki B.M., Schadendorf D. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur. J. Immunol. 1995, 25:3100-3107.
138. Madueno J.A., Munoz E., Blazquez V., Gonzalez R., Aparicio P., Pena J. The CD26 antigen is coupled to protein tyrosine phosphorylation and implicated in CD16-mediated lysis in natural killer cells. Scand. J. Immunol. 1993, 37:425-429.
139. Shingu K., Helfritz A., Zielinska-Skowronek M., Meyer-Olson D., Jacobs R., Schmidt R.E., Mentlein R., Pabst R., von Horsten S. CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26. Cancer Immunol. Immunother. 2003, 52:546-554.
140. Tanaka T., Duke-Cohan J.S., Kameoka J., Yaron A., Lee I., Schlossman S.F., Morimoto C. Enhancement of antigen-induced T cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc. Natl. Acad. Sci. USA 1994, 91:3082-3086.
141. van der Velden V.H., Wierenga-Wolf A.F., Adriaansen-Soeting P.W., Overbeek S.E., Moller G.M., Hoogsteden H.C., Versnel M.A. Expression of aminopeptidase N and dipeptidyl peptidase IV in the healthy and asthmatic bronchus. Clin. Exp. Allergy 1998, 28:110-120.
142. Jarmolowska B., Bielikowicz K., Iwan M., Sidor K., Kostyra E., Kaczmarski M. Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) in breast-fed infants with symptoms of allergy. Peptides 2007, 28:678-682.
143. Katoh N., Hirano S., Suehiro M., Ikenaga K., Yamashita T., Sugawara N., Yasuno H. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin. Exp. Immunol. 2000, 121:187-192.
144. Eguchi K., Ueki Y., Shimomura C., Otsubo T., Nakao H., Migita K., Kawakami A., Matsunaga M., Tezuka H., Ishikawa N. Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. J. Immunol. 1989, 142:4233-4240.
145. Xiao Q., Boushey R.P., Cino M., Drucker D.J., Brubaker P.L. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am. J. Physiol. 2000, 278:R1057-R1063.
146. Steinbrecher A., Reinhold D., Quigley L., Gado A., Tresser N., Izikson L., Born I., Faust J., Neubert K., Martin R., Ansorge S., Brocke S. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J. Immunol. 2001, 166:2041-2048.
147. Bock O., Kreiselmeyer I., Mrowietz U. Expression of dipeptidyl-peptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis. Exp. Dermatol. 2001, 10:414-419.
148. Busso N., Wagtmann N., Herling C., Chobaz-Peclat V., Bischof-Delaloye A., So A., Grouzmann E. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am. J. Pathol. 2005, 166:433-442.
149. Cordero O.J., Salgado F.J., Mera-Varela A., Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol. Int. 2001, 21:69-74.
150. Stancikova M., Lojda Z., Lukac J., Ruzickova M. Dipeptidyl peptidase IV in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 1992, 10:381-385.
151. Tamaki Z., Kubo M., Yazawa N., Mimura Y., Ashida R., Tomita M., Tada Y., Kawashima T., Tamaki K. Serum levels of soluble CD26 in patients with scleroderma. J. Dermatol. Sci. 2008, 52:67-69.
152. Muller A., Trabandt A., Gloeckner-Hofmann K., Seitzer U., Csernok E., Schonermarck U., Feller A.C., Gross W.L. Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J. Pathol. 2000, 192:113-120.
153. Schonermarck U., Csernok E., Trabandt A., Hansen H., Gross W.L. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin. Exp. Rheumatol. 2000, 18:457-463.
154. Joseph A., Brasington R., Kahl L., Ranganathan P., Cheng T.P., Atkinson J. Immunologic rheumatic disorders. J. Allergy Clin. Immunol. 2010, 125:S204-S215.
155. Mavropoulos J.C., Cuchacovich M., Llanos C., Aguillon J.C., Gatica H., Pizzo S.V., Gonzalez-Gronow M. Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. J. Rheumatol. 2005, 32:2116-2124.
156. Wolf M., Albrecht S., Marki C. Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int. J. Biochem. Cell Biol. 2008, 40:1185-1198.
157. Kim K.W., Cho M.L., Kim H.R., Ju J.H., Park M.K., Oh H.J., Kim J.S., Park S.H., Lee S.H., Kim H.Y. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L - CD40 interaction. Arthritis Rheum. 2007, 56:1076-1086.
158. Ohnuma K., Inoue H., Uchiyama M., Yamochi T., Hosono O., Dang N.H., Morimoto C. T cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod. Rheumatol. 2006, 16:3-13.
159. Tanaka S., Murakami T., Horikawa H., Sugiura M., Kawashima K., Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 1997, 19:15-24.
160. Tanaka S., Murakami T., Nonaka N., Ohnuki T., Yamada M., Sugita T. Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology 1998, 40:21-26.
161. Ramagopalan S.V., Dobson R., Meier U.C., Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010, 9:727-739.
162. Hafler D.A., Fox D.A., Manning M.E., Schlossman S.F., Reinherz E.L., Weiner H.L. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N. Engl. J. Med. 1985, 312:1405-1411.
163. Krakauer M., Sorensen P.S., Sellebjerg F. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J. Neuroimmunol. 2006, 181:157-164.
164. Reinhold D., Biton A., Pieper S., Lendeckel U., Faust J., Neubert K., Bank U., Tager M., Ansorge S., Brocke S. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int. Immunopharmacol. 2006, 6:1935-1942.
165. Preller V., Gerber A., Wrenger S., Togni M., Marguet D., Tadje J., Lendeckel U., Rocken C., Faust J., Neubert K., Schraven B., Martin R., Ansorge S., Brocke S., Reinhold D. TGF-β1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J. Immunol. 2007, 178:4632-4640.
166. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010, 28:573-621.
167. Varljen J., Sincic B.M., Baticic L., Varljen N., Detel D., Lekic A. Clinical relevance of the serum dipeptidyl peptidase IV (DPP IV/CD26) activity in adult patients with Crohn's disease and ulcerative colitis. Croat. Chem. Acta 2005, 78:427-432.
168. Rose M., Hildebrandt M., Fliege H., Seibold S., Monnikes H., Klapp B.F. T cell immune parameters and depression in patients with Crohn's disease. J. Clin. Gastroenterol. 2002, 34:40-48.
169. Geier M.S., Tenikoff D., Yazbeck R., McCaughan G.W., Abbott C.A., Howarth G.S. Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J. Cell. Physiol. 2005, 204:687-692.
170. Bank U., Bohr U.R., Reinhold D., Lendeckel U., Ansorge S., Malfertheiner P., Tager M. Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors. Front. Biosci. 2008, 13:3699-3713.
171. Yazbeck R., Howarth G.S., Geier M.S., Demuth H.U., Abbott C.A. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front. Biosci. 2008, 13:6850-6858.
172. Lehuen A., Diana J., Zaccone P., Cooke A. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 2010, 10:501-513.
173. Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul. Pept. 2005, 128:149-157.
174. Dupre J., Behme M.T., Hramiak I.M., McFarlane P., Williamson M.P., Zabel P., McDonald T.J. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995, 44:626-630.
175. Pospisilik J.A., Ehses J.A., Doty T., McIntosh C.H., Demuth H.U., Pederson R.A. Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv. Exp. Med. Biol. 2003, 524:281-291.
176. Pospisilik J.A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., Piteau S., Demuth H.U., McIntosh C.H., Pederson R.A. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52:741-750.
177. Issa F., Schiopu A., Wood K.J. Role of T cells in graft rejection and transplantation tolerance. Expert Rev. Clin. Immunol. 2010, 6:155-169.
178. Korom S., De Meester I., Stadlbauer T.H., Chandraker A., Schaub M., Sayegh M.H., Belyaev A., Haemers A., Scharpe S., Kupiec-Weglinski J.W. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997, 63:1495-1500.
179. Jungraithmayr W., De Meester I., Matheeussen V., Inci I., Augustyns K., Scharpe S., Weder W., Korom S. Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: the pivotal role of vasoactive intestinal peptide. Peptides 2010, 31:585-591.
180. Jungraithmayr W., Oberreiter B., De Meester I., Wiedl T., Inci I., Bain M., Augustyns K., Hillinger S., Scharpe S., Weder W., Korom S. The effect of organ-specific CD26/DPP IV enzymatic activity inhibitor-preconditioning on acute pulmonary allograft rejection. Transplantation 2009, 88:478-485.
181. Mackall C.L., Gress R.E. Pathways of T cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol. Rev. 1997, 157:61-72.
182. Shlomchik W.D. Graft-versus-host disease. Nat. Rev. Immunol. 2007, 7:340-352.
183. Bacigalupo A., Corte G., Ramarli D., van Lint M.T., Frassoni F., Marmont A. Intravenous monoclonal antibody (BT 5/9) for the treatment of acute graft-versus-host disease. Acta Haematol. 1985, 73:185-186.
184. de Meester I., Scharpe S., Vanham G., Bosmans E., Heyligen H., Vanhoof G., Corte G. Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster. Immunobiology 1993, 188:145-158.
185. Gorrell M.D., Gysbers V., McCaughan G.W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 2001, 54:249-264.
186. Wong P.T., Wong C.K., Tam L.S., Li E.K., Chen D.P., Lam C.W. Decreased expression of T lymphocyte co-stimulatory molecule CD26 on invariant natural killer T cells in systemic lupus erythematosus. Immunol. Investig. 2009, 38:350-364.
187. Kubota T., Iizuka H., Bachovchin W.W., Stollar B.D. Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin. Exp. Immunol. 1994, 96:292-296.
188. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J. Dermatol. 2010, 37:11-25.
189. Bermpohl F., Loster K., Reutter W., Baum O. Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens. FEBS Lett. 1998, 428:152-156.
190. Thielitz A., Vetter R.W., Schultze B., Wrenger S., Simeoni L., Ansorge S., Neubert K., Faust J., Lindenlaub P., Gollnick H.P., Reinhold D. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. J. Investig. Dermatol. 2008, 128:855-866.
191. Lane H.C., Depper J.M., Greene W.C., Whalen G., Waldmann T.A., Fauci A.S. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N. Engl. J. Med. 1985, 313:79-84.
192. van Noesel C.J., Gruters R.A., Terpstra F.G., Schellekens P.T., van Lier R.A., Miedema F. Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. J. Clin. Invest. 1990, 86:293-299.
193. Blazquez M.V., Madueno J.A., Gonzalez R., Jurado R., Bachovchin W.W., Pena J., Munoz E. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J. Immunol. 1992, 149:3073-3077.
194. Gougeon M.L., Lecoeur H., Callebaut C., Jacotot E., Dulioust A., Roue R., Montagnier L., Hovanessian A.G. Selective loss of the CD4+/CD26+ T cell subset during HIV infection. Res. Immunol. 1996, 147:5-8.
195. Cullen B.R. Does HIV-1 Tat induce a change in viral initiation rights?. Cell 1993, 73:417-420.
196. Viscidi R.P., Mayur K., Lederman H.M., Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989, 246:1606-1608.